An analysis of published patent applications in chimeric antigen receptor (CAR) T-cell immunotherapy allows insight into the development of this emerging technology.
Change history
09 April 2019
In the version of this article initially published online, the abstract read “dedvelopment” instead of “development” as a result of a publisher error. The error has been corrected in the print, PDF and HTML versions of this article.
References
Kolata, G. New gene-therapy treatments will carry whopping price tags. The New York Times https://www.nytimes.com/2017/09/11/health/cost-gene-therapy-drugs.html (11 September 2017).
Grady, D. Companies rush to develop ‘utterly transformative’ gene therapies. The New York Times https://www.nytimes.com/2017/07/23/health/gene-therapy-cancer.html (23 July 2017).
Sadelain, M. & Rivière, I. CAR T cells in cancer therapy (poster). Nat. Rev. Drug Disc. (December 2017).
Golstein, P. & Griffiths, G. M. Nat. Rev. Immunol. 18, 527–535 (2018).
Mullard, A. Nat. Rev. Drug Discov. 14, 301 (2015).
Morrison, C. Nat. Biotechnol. 33, 571–572 (2015).
Dolgin, E. Nat. Biotechnol. 35, 891–892 (2017).
Trippe, A. Guidelines for Preparing Patent Landscape Reports (World Intellectual Property Organization, 2015).
Zuniga, P. et al. OECD Patent Statistics Manual (OECD, 2009).
European IPR Helpdesk. E-IPR fact sheet: automatic patent analysis. https://www.iprhelpdesk.eu/sites/default/files/newsdocuments/Fact-Sheet-Automatic-Patent-Analysis.pdf (2013).
Jürgens, B. & Herrero-Solana, V. J. Intell. Stud. Bus. 7, 17–26 (2017).
Dara, A. & Sangamwar, A. T. PLoS One 9, e103847 (2014).
Pan, C. L. & Chen, F. C. Hum. Vaccin. Immunother. 13, 2583–2593 (2017).
Anaya, M., Perez-Santos, M. & Muñoz-Rojas, J. Intl. J. Cancer Biol. Clin. Oncol. 1, 14–18 (2017).
Anonymous. Nat. Biotechnol. 35, 215 (2017).
Bouchie, A., Allison, M., Webb, S. & DeFrancesco, L. Nat. Biotechnol. 32, 229–238 (2014).
Bouchie, A. & DeFrancesco, L. Nat. Biotechnol. 33, 247–255 (2015).
Morrison, C. Nat. Biotechnol. 36, 131–136 (2018).
Yeager, A.J. CAR-T in the courts. Genetic Engineering News (11 September 2017).
Acknowledgements
This article is based on a study that was commissioned by the European Patent Office with the aim of demonstrating to readers outside the disciplines of patent analysis and CAR T-cell immunotherapy how patent information can be used to gain insight and competitive advantages about a specific technological field. The authors thank F. Aslund, P. Bumb and D. Manu from the European Patent Office for their support in the classification identification process and assistance for fine-tuning the search strategy. The opinions expressed in this article are those of the authors and not necessarily those of their employers.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Supplementary Information
Supplementary Methods
Rights and permissions
About this article
Cite this article
Jürgens, B., Clarke, N.S. Evolution of CAR T-cell immunotherapy in terms of patenting activity. Nat Biotechnol 37, 370–375 (2019). https://doi.org/10.1038/s41587-019-0083-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-019-0083-5
- Springer Nature America, Inc.
This article is cited by
-
The global patent landscape of mRNA for diagnosis and therapy
Nature Biotechnology (2023)
-
Biomarkers in individualized management of chimeric antigen receptor T cell therapy
Biomarker Research (2020)
-
Value and affordability of CAR T-cell therapy in the United States
Bone Marrow Transplantation (2020)
-
Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
Leukemia (2020)
-
The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape
Nature Biotechnology (2020)